Publications by authors named "S Gardin"
Background: Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality and hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact of these antivirals in the Omicron era. We conducted a pharmacoeconomic analysis assessing the medical costs of the use of these antivirals compared to those occurred in people who refused the treatment.
View Article and Find Full Text PDFBackground: The introduction of rapid antigen tests revolutionized the approach to SARS-CoV-2 diagnosis, offering prompt and accurate results with high sensitivity and specificity. Although it is more cost- and time-saving than the gold standard, real-time polymerase chain reaction (RT-PCR), the efficacy in general population screening in both hospital- and community-based settings remains unknown. Moreover, rapid antigen testing is limited by qualitative results.
View Article and Find Full Text PDFArticle Synopsis
- Injectable cabotegravir/rilpivirine (ICAB/RPV) has recently become available for HIV treatment, and this study aimed to evaluate its impact on sleep disturbances in patients who switched to this therapy.
- A total of 46 individuals participated, and they were assessed for sleep quality before and 12 weeks after starting ICAB/RPV using various sleep questionnaires; the demographic data and health records were also analyzed.
- Results showed no significant changes in sleep disturbance scores, although 37% reported feeling their sleep quality improved, indicating that switching to ICAB/RPV might have minimal negative effects on sleep despite previous concerns.
Article Synopsis
- Clinical trials showed that dolutegravir and lamivudine (DTG/3TC) are effective and safe for people living with HIV, but there’s a lack of long-term data for individuals aged 65 and older.
- A study involving 112 participants aged 65 and above found that most had multimorbidity, and after switching to DTG/3TC, there were no significant changes in health parameters over a 6-year follow-up.
- The study concluded that DTG/3TC is safe and effective for older adults with HIV, maintaining a high rate of undetectable viral loads and a low rate of treatment discontinuations due to side effects or virological failure.*
Recently, a benefit from administration of a 3-day course of early remdesivir (ER) in the outpatients' setting was reported. However, real-life data on its use is scarce. Therefore, we explored the ER clinical outcome in our outpatients' s cohort, compared to untreated controls.
View Article and Find Full Text PDF